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Abstract Early detection of primary melanoma tumors is
essential because there is no effective treatment for meta-
static melanoma. Several linear and cyclic radiolabeled a-
melanocyte stimulating hormone (a-MSH) analogs have
been proposed to target the melanocortin type 1 receptor
(MC1R) overexpressed in melanoma. The compact struc-
ture of a rhenium-cyclized a-MSH analog (Re-CCMSH)
significantly enhanced its in vivo tumor uptake and reten-
tion. Melanotan II (MT-II), a cyclic lactam analog of a-
MSH (Ac-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH2]), is
a very potent and stable agonist peptide largely used in the
characterization of melanocortin receptors. Taking advan-
tage of the superior biological features associated with the
MT-II cyclic peptide, we assessed the effect of lactam-
based cyclization on the tumor-seeking properties of a-
MSH analogs by comparing the pharmacokinetics profile of
the 99mTc-labeled cyclic peptide bAla-Nle-cyclo[Asp-His-
D-Phe-Arg-Trp-Lys]-NH2 with that of the linear analog
bAla-Nle-Asp-His-DPhe-Arg-Trp-Lys-NH2 in melanoma-
bearing mice. We have synthesized and coupled the linear
and cyclic peptides to a bifunctional chelator containing a
pyrazolyl-diamine backbone (pz) through the amino group
of bAla, and the resulting pz–peptide conjugates were
reacted with the fac-[99mTc(CO)3]
+ moiety. The
99mTc(CO)3-labeled conjugates were obtained in high yield,
high specific activity, and high radiochemical purity. The
cyclic 99mTc(CO)3-labeled conjugate presents a remarkable
internalization (87.1% of receptor-bound tracer and 50.5%
of total applied activity, after 6 h at 37 C) and cellular
retention (only 24.7% released from the cells after 5 h) in
murine melanoma B16F1 cells. A significant tumor uptake
and retention was obtained in melanoma-bearing C57BL6
mice for the cyclic radioconjugate [9.26 ± 0.83 and
11.31 ± 1.83% ID/g at 1 and 4 h after injection, respec-
tively]. The linear 99mTc(CO)3-pz–peptide presented lower
values for both cellular internalization and tumor uptake.
Receptor blocking studies with the potent (Nle4,DPhe7)-
aMSH agonist demonstrated the specificity of the radio-
conjugates to MC1R (74.8 and 44.5% reduction of tumor
uptake at 4 h after injection for cyclic and linear radio-
conjugates, respectively).
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HPLC High-performance liquid chromatography
ID Injected dose
MC1R Melanocortin type 1 receptor
MEM Modified Eagle’s medium
MT-II Melanotan II
NAPamide [Ac–Nle4,Asp5,DPhe7]–aMSH4–11
NDP-MSH (Nle4,DPhe7)-aMSH
PBS Phosphate-bufered saline
pz Tridentate ligand containing a
pyrazolyl-diamine backbone
RP Reversed phase
TBTU O-(Benzotriazol-1-yl)-N,N,N0,N0-
tetramethyluronium tetrafluoroborate
TFA Trifluoroacetic acid
TLC Thin-layer chromatography
Introduction
The incidence and mortality rates of cutaneous melanoma
are still increasing in most western countries. Early detec-
tion of primary melanoma tumors is essential, since the
current treatments do not enhance substantially patient
survival once metastasis has occurred [1]. Fluoro-2-de-
oxyglucose (18F-FDG), the most widely used positron-
emitter radiopharmaceutical, is limited in detecting mela-
noma tumors with small foci [2], and some melanoma cells
are undetectable with 18F-FDG because they use substrates
other than glucose as an energy source [3]. Therefore,
development of new melanoma-specific radiopharmaceuti-
cals for imaging or internal radiotherapy is a subject of great
interest and intense research. It has been reported that most
murine and human melanoma metastasis bear upregulated
a-melanocyte stimulating hormone (a-MSH) receptors,
namely, the melanocortin type 1 receptor (MC1R) [4–6].
Since radiopeptides have proven their superior usefulness as
radioactive probes for cancer diagnosis and internal radio-
therapy, a significant research effort has been directed to the
development of radiolabeled a-MSH analogs for diagnosis
and treatment of melanoma [7–23]. The tridecapeptide a-
MSH, the most potent naturally occurring melanotropic
peptide and the most active peptide of MC1R [24], has a
short half-life in humans, as do many other endogenous
peptides (Table 1). The minimal sequence required for
biological activity was determined by structure–bioactivity
studies to be His-Phe-Arg-Trp, and the replacement of Met4
and Phe7 by Nle and DPhe, respectively, led to the more
potent (Nle4,DPhe7)–aMSH (NDP-MSH) analog (Table 1),
which is enzymatically stable and has a longer half-life [25].
Introduction of a cyclic constraint in a lead peptide may
restrict the flexibility and favor peptide–receptor interac-
tions, and is an effective way of generating ligands with
enhanced potency, receptor selectivity, and enzymatic
stability [25]. The concept of side chain to side chain
cyclization of melanocortin peptides has been successfully
applied, namely, in the case of Ac–[Cys4,Cys10]–aMSH,
which contains a disulfide bridge between Cys4 and Cys10
amino acids [25]. Another very potent peptide agonist, also
used in the characterization of melanocortin receptors, is
the cyclic lactam analog melanotan II (MT-II; Table 1)
[25].
For potential medical application, some linear a-MSH
analogs have been labeled with the radiometals 111In, 67Ga,
64Cu, and 99mTc via an indirect approach using 1,4,7,10-
tetraazacyclododecane-N,N0,N00,N000-tetracetic acid (DOTA)
or a pyrazolyl-containing ligand as bifunctional chelators
[7–9, 19, 20]. To take advantage of the superior biological
properties presented by the cyclic peptides, a new family of
Re- and Tc-based cyclic a-MSH analogs, MO[Cys3,4,10,
DPhe7]–a-MSH3–13 [M-CCMSH] (M is Re,
99mTc) has
been developed for melanoma targeting [10, 16, 17]. The
biological evaluation of the cyclic radioanalogs, 99mTc-
CCMSH and 111In-DOTA-ReCCMSH, has shown a
significant tumor uptake but also a high kidney accumu-
lation. Substitution of Lys11 by Arg11 led to the
radioanalogs 99mTc-CCMSH(Arg11) and 111In-DOTA-
ReCCMSH(Arg11), which have shown higher tumor uptake
and lower kidney accumulation, potentially interesting
imaging probes for primary and pulmonary metastatic
melanoma detection [11, 18]. These analogs were also
labeled with therapeutic radionuclides (188Re and 212Pb)
and their tumor uptake and therapeutic efficacy were
evaluated in melanoma models [12, 13, 21, 22]. For PET
imaging of melanoma the cyclic ReCCMSH(Arg11) pep-
tide was labeled with 64Cu, using DOTA and a cross-
bridged cyclam (CBTE2A) as bifunctional chelators [15,
23].
These results taken together showed that metal-based
cyclization improves the biological behavior of the radio-
labeled a-MSH analogs. Furthermore, the high MC1R
affinity, stability, and prolonged activity of the cyclic MT-
II agonist prompted us to explore the 99mTc(CO)3-labeling
and evaluation of the biological properties of an analog of
MT-II, the cyclic peptide bAla-Nle-cyclo[Asp-His-DPhe-
Arg-Trp-Lys]–NH2, as well as the advantages of the
lactam-based cyclization by comparison with the corre-
sponding linear peptide.
Thus, in this paper, we report on the synthesis and
characterization of the cyclic (pz-bAla-Nle-cyclo[Asp-His-
D-Phe-Arg-Trp-Lys]-NH2) and linear (pz-bAla-Nle-Asp-
His-D-Phe-Arg-Trp-Lys-NH2) peptide conjugates, as well
as on their radiolabeling with the fac-[99mTc(CO)3]
+ core, a
quite versatile synthon for labeling different types of bio-
active molecules, including peptides [20, 26–34]. The
bifunctional chelating agent used for metal stabilization
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(pz) was a tridentate ligand containing a pyrazolyl-diamine
backbone, which has been used with success in the radio-
labeling of several other peptides, including the a-MSH
analog [Ac–Nle4,Asp5,DPhe7]–aMSH4–11 (NAPamide) [20,
31–34]. We also describe the in vitro/in vivo stability
studies, internalization/externalization in B16F1 cells, and
biodistribution in murine melanoma-bearing mice of the
radiolabeled conjugates. The advantages of using
99mTc(CO)3-labeled cyclic analogs over the corresponding
linear analogs for melanoma targeting are discussed.
Materials and methods
Materials
NDP-MSH was purchased from Neosystem (Strasbourg,
France). Bovine serum albumin (BSA) was purchased from
Sigma. Dulbecco’s modified Eagle’s medium (DMEM)
containing GlutaMax I, fetal bovine serum, penicillin/
streptomycin antibiotic solution, trypsin–EDTA, and
phosphate-buffered saline (PBS) pH 7.2 were all from
Gibco–Invitrogen (Alfagene, Lisbon).
Pyrazolyl-peptide conjugates: synthesis
and characterization
The tert-butoxycarbonyl (Boc) protected pyrazolyl ligand
(Me2pzN[(CH2)3COOH]NH-Boc or Boc-pz) was prepared
as previously described [31, 32]. The linear conjugate pz-
bAla-Nle-Asp-His-DPhe-Arg-Trp-Lys-NH2 was prepared
by 9-fluorenylmethoxycarbonyl (Fmoc)/t-Bu solid-phase
peptide synthesis on a Rink amide resin using the
appropriate Na-Fmoc-protected amino acids and O-(ben-
zotriazol-1-yl)-N,N,N0,N0-tetramethyluronium tetrafluoro-
borate (TBTU) as a coupling agent [35, 36]. Boc-pz was
incorporated on-resin to the N-terminus after assembly of
the amino acid sequence. The conjugate, pz-bAla-Nle-
Asp-His-DPhe-Arg-Trp-Lys-NH2, was cleaved from the
resin by acidolytic treatment with a cocktail having 95%
trifluoroacetic acid (TFA) and appropriate scavengers
(e.g., triethylsilane) to capture any reactive undesired
species formed. The Boc group was also removed in the
acidolysis.
The cyclic conjugate pz-bAla-Nle-cyclo[Asp-His-DPhe-
Arg-Trp-Lys]-NH2 was also prepared by standard Fmoc/
t-
Bu solid-phase peptide synthesis using the specially pro-
tected Fmoc-Asp(ODmab)-OH and Fmoc-Lys(ivDde)-OH
amino acid derivatives in order to allow on-resin cycliza-
tion prior to cleavage and full deprotection of the final
peptide [37–39]. Briefly, the linear peptide sequence was
normally assembled on a Fmoc–Rink–MBHA resin
(0.30 mmol/g) up until the incorporation of Fmoc-
Asp(ODmab)-OH, using TBTU as a coupling agent and
20% piperidine in dimethlyformamide for Fmoc-removal
cycles [37]. Once Fmoc-Asp(ODmab) had been quantita-
tively incorporated in the peptidyl resin, this was treated
with a freshly prepared mixture of hydroxylamine hydro-
chloride and imidazole in N-methylpyrrolidone to
accomplish the selective and simultaneous removal of the
ODmab and ivDde side chain protecting groups [40]
(P. Gomes et al., unpublished results). Condensation of the
Asp and Lys side chains to form the intramolecular lactam
bridge was carried out using (benzotriazol-1-yloxy)tri-
pyrrolidinophosphonium hexafluorophosphate (6 equiv),
diisopropylethylamine (12 equiv), and 1-hydroxybenzotri-
azole (6 equiv) [37]. After lactamization had reached
completion, normal assembly of the remaining peptide
chain was resumed up to the quantitative incorporation of
the N-terminal Boc-pz ligand. Full deprotection and
cleavage of the final peptide from the solid support was
performed by treatment of the peptidyl resin with TFA
containing 2.5% H2O and 2.5% triisopropylsilane. The
crude product was purified by semipreparative reversed-
phase (RP) high-performance liquid chromatography
(HPLC) (better than 97%) and successfully characterized
as the target peptide by amino acid analysis and electro-
spray ionization mass spectrometry (ESI–MS). Linear
conjugate—calcd m/z for [M]+: 1,320.76; found: 1,321.6
[M + H]+. Cyclic conjugate—calcd m/z for [M]+ 1,302.75;
found: 1,303.87 [M + H]+.
Table 1 Structure of
a-melanocyte stimulating
hormone (a-MSH) and some
a-MSH analogs
Bold: amino acids residues
replaced in different analogs
relatively to the endogeneous
peptide (aMSH); underline:
minimal sequence for biological
activity
Peptide No. of amino
acids
Ac-Ser-Tyr-Ser-Met4-Glu5-His-Phe7-Arg-Trp-Gly-Lys-Pro-Val-NH2 (a-MSH) 13
Ac-Ser-Tyr-Ser-Nle4-Glu5-His-DPhe7-Arg-Trp-Gly-Lys-Pro-Val-NH2 (NDP-MSH) 13
Ac-Cys3-Cys4-Glu5-His-DPhe7-Arg-Trp-Cys10-Lys-Pro-Val-NH2 (CCMSH) 11
Ac-Cys3-Cys4-Glu5-His-DPhe7-Arg-Trp-Cys10-Arg11-Pro-Val-NH2 [CCMSH(Arg
11)] 11
Ac-Nle4-cyclo[Asp5-His-DPhe7-Arg-Trp-Lys10]-NH2 (MT-II) 7
bAla3-Nle4-cyclo[Asp5-His-DPhe7-Arg-Trp-Lys10]-NH2 (1) 8
bAla3-Nle4-Asp5-His-DPhe7-Arg-Trp-Lys10-NH2 (2) 8
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Radiolabeling
Na[99mTcO4] was eluted from a
99Mo/99mTc generator, using
0.9% saline. The preparation of fac-[99mTc(CO)3(H2O)3]
+
was done according to a previously described procedure,
using an Isolink kit (Mallinckrodt) [31, 32]. In a nitrogen-
purged glass vial, 100 lL of a 6 9 10-4 M solution of the
conjugate pz–aMSH analog was added to 900 lL of a
solution of fac-[99mTc(CO)3(H2O)3]
+ (37–74 MBq) in PBS.
The reaction mixture was incubated at 90 or 100 C for 50 or
60 min, for the cyclic and linear conjugates respectively, and
then analyzed by RP-HPLC, using an analytical C-18 RP
column. The radiolabeled compound was purified by semi-
preparative RP-HPLC. The activity corresponding to the
99mTc(CO)3-conjugate was collected in a 50 mL Falcon
flask containing 200 lL of PBS with 0.2% BSA or modified
Eagle’s medium (MEM) with 0.2% BSA, for biodistribution
or internalization studies, respectively. The solutions were
concentrated to a final volume of 200 lL under a nitrogen
stream, and the product was checked by thin-layer chroma-
tography and HPLC (see in vitro stability), to confirm its
purity and stability after purification and evaporation.
HPLC analysis
RP-HPLC was performed using a PerkinElmer system (LC-
Pump, series 200) coupled to a UV–vis detector (LC 290,
PerkinElmer or SDP-10AV, Shimadzu) and a c-detector
(LB 507 or LB 509, Berthold) for the 99mTc compounds.
Analytical separations were achieved on a Hypersil ODS
column (250 mm 9 4 mm, 10 lm). Semipreparative sep-
arations of the radioactive complexes were achieved on a
Hypersil ODS column (250 mm 9 8 mm, 10 lm). The
contents of the columns were eluted with a binary gradient
system with a flow rate of 1.0 mL/min (analytical), 2.0 mL/
min (semipreparative for the linear radioconjugate) or
3.0 mL/min (semipreparative for the cyclic radioconju-
gate). Mobile phase A was 0.5% TFA and mobile phase B
was CH3CN, 0.5% TFA. The method for the analytical
control of the radioconjugates was as follows: 0–18 min,
15–100% mobile phase B; 18–20 min, 100–15% mobile
phase B; 20–30 min, 15% mobile phase B. The method for
semipreparative separation of the linear radioconjugate was
as follows: 0–3 min, 0% mobile phase B; 3–3.1 min, 0–
25% mobile phase B; 3.1–9 min, 25% mobile phase B; 9–
9.1 min, 25–34% mobile phase B; 9.1–14.1 min, 34–100%
mobile phase B; 14.1–19 min, 100% mobile phase B; 19–
21 min, 100–0% mobile phase B. The method for the
semipreparative separation of the cyclic radioconjugate was
as follows: 0–15 min, 15–30% mobile phase B; 15–30 min,
30% mobile phase B; 30–45 min 30–60% mobile phase B,
45–60 min 60% mobile phase B.
Thin-layer chromatography analysis
Thin-layer chromatography (TLC) was performed using
silica gel TLC strips (Polygram Sil G, Macherey–Nagel)
developed with a mobile phase of 5% 6 N HCl in metha-
nol. Radioactive distribution on the TLC strips was
detected using a Berthold LB 505 detector coupled to a
radiochromatogram scanner.
Partition coefficient
The lipophilicity of the radioconjugates was evaluated by
the ‘‘shakeflask’’ method [41]. The radioconjugates were
added to a mixture of octanol (1 mL) and 0.1 M PBS pH
7.4 (1 mL), previously saturated in each other by stirring
the mixture (1 min). This mixture was vortexed and cen-
trifuged (3,000 rpm, 10 min, room temperature) to allow
phase separation. Aliquots of both octanol and PBS were
counted using a c-counter. The partition coefficient (Po/w)
was calculated by dividing the counts in the octanol phase
by those in the buffer, and the results were expressed as log
Po/w.
In vitro stability
The in vitro stability of the radioconjugates was determined
in fresh human plasma. The radioconjugates (100 lL,
approximately 10 MBq) were added to fresh human plasma
(1 mL), and the mixtures were incubated at 37 C. At
appropriate time points (5 min, 45 min, and 4 h), 100 lL
aliquots (in duplicate) were sampled and treated with
200 lL of ethanol to precipitate the proteins. Samples were
centrifuged at 3,000 rpm for 15 min at 4 C. The superna-
tant was analyzed by HPLC. The stability of the
radiolabeled conjugates in the solutions containing 0.2%
BSA was checked by HPLC (column, Supelguard LC 3 DP
2 cm 9 4.6-mm inner diameter; eluents, A—10% 2-pro-
panol and 90% 0.1% TFA, B—90% 2-propanol and 10%
0.1% TFA ; flux, 1 mL/min) and TLC (5% 6 N HCl/MeOH).
Cell culture
B16F1 murine melanoma cells (ECACC, UK) were grown
in DMEM containing GlutaMax I supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin/
streptomycin antibitiotic solution (all from Gibco, Alfa-
gene, Lisbon). Cells were cultured in a humidified
atmosphere of 95% air and 5% CO2 at 37 C (Heraeus,
Germany), with the medium changed every other day. The
cells were adherent in monolayers and, when confluent,
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were harvested from the cell culture flasks with trypsin–
EDTA (Gibco, Alfagene, Lisbon) and seeded farther apart.
Internalization and cellular retention studies
Internalization assays of the radioconjugates were per-
formed in B16F1 murine melanoma cells seeded at a
density of 0.2 million per well in 24-well tissue culture
plates and allowed to attach overnight. The cells were
incubated at room temperature or 37 C for a period of
5 min to 6 h with about 200,000 cpm of the conjugate in
0.5 mL of assay medium [MEM with 25 mM N-(2-
hydroxyethyl)piperazine-N0-ethanesulfonic acid and 0.2%
BSA]. Incubation was terminated by washing the cells with
ice-cold assay medium. Cell-surface-bound radioligand
was removed by two steps of acid wash (50 mM glycine,
HCl/100 mM NaCl, pH 2.8) at room temperature for
5 min. The pH was neutralized with cold PBS with 0.2%
BSA, and subsequently the cells were lysed by 10 min
incubation with 1 N NaOH at 37 C to determine inter-
nalized radioligand. The cellular retention properties of the
internalized radioconjugates were determined by incubat-
ing B16F1 cells with the radiolabeled compound for 3 h at
37 C, washing them with cold assay medium, removing
the membrane-bound radioactivity with acid buffer wash,
and monitoring radioactivity release into the culture media
(0.5 mL) at 37 C. At different time points over a 5 h
incubation period, the radioactivity in the medium and that
in the cells were separately collected and counted.
Biodistribution
All animal experiments were performed in compliance
with Portuguese regulations for animal treatment. The
animals were housed in a temperature- and humidity-con-
trolled room with a 12 h light/12 h dark schedule.
Biodistribution of the radioconjugates was estimated in
healthy and melanoma-bearing C57BL/6 female mice (8–
10 weeks old). Mice were previously implanted subcuta-
neously with 1 9 106 B16F1 cells to generate a primary
skin melanoma. Ten to 12 days after the inoculation,
tumors reached a weight of 0.2–1 g.
Animals were intravenously injected into the retroorbital
sinus with the radiolabeled complex (3–10 MBq) diluted in
100 lL of PBS pH 7.2. For confirming the specific uptake,
10 lg of NDP-MSH was coinjected with the radioactive
complex. The effect of L-Lys coinjection on nonspecific
kidney uptake of the peptide was examined in healthy
C57BL/6 female mice. The animals were injected with a
mixture of 3 MBq of cyclic labeled conjugate with 15 mg
of L-Lys.
Mice were killed by cervical dislocation at 1, 4, and
24 h after injection. The dose administered and the radio-
activity in the killed animals were measured using a dose
calibrator (Curiemeter IGC-3, Aloka, Tokyo, Japan or
Carpintec CRC-15W, Ramsey, USA). The difference
between the radioactivity in the injected and that in the
killed animals was assumed to be due to excretion. Tumors
and normal tissues of interest were dissected, rinsed to
remove excess blood, weighed, and their radioactivity was
measured using a c-counter (LB2111, Berthold, Germany).
The uptake in the tumor and healthy tissues of interest was
calculated and expressed as a percentage of the injected
radioactivity dose per gram of tissue. For blood, bone,
muscle, and skin, total activity was estimated assuming that
these organs constitute 6, 10, 40, and 15% of the total body
weight, respectively. Urine was also collected and pooled
together at the time the animals were killed.
In vivo stability
The stability of the complexes was assessed by urine, and
murine serum RP-HPLC analysis, under identical condi-
tions to those used for analyzing the original radiolabeled
complexes. The samples were taken 1 h after injection. The
urine collected at the time the mice were killed was filtered
through a Millex GV filter (0.22 lm) before RP-HPLC
analysis. Blood collected from the mice was centrifuged at
3,000 rpm for 15 min at 4 C, and the serum was separated.
The serum was treated with ethanol in a 2:1 (v/v) ratio to
precipitate the proteins. After centrifugation at 3,000 rpm
for 15 min at 4 C, the supernatant was collected and
analyzed by RP-HPLC.
Results and discussion
The presence of a-MSH receptors on melanoma cells and
the fact that the receptors undergo rapid internalization on
ligand binding have led researchers to explore the possi-
bility of using radiolabeled a-MSH analogs for melanoma
diagnosis or therapy. Encouraging data on the use of cyclic
Re-CCMSH peptides and peptide labeling with the fac-
[99mTc(CO)3]
+ moiety through the bifunctional chelating
approach led us to consider the possibility of developing a
new class of melanoma-specific 99mTc(CO3)-labeled
a-MSH analogs based on the MT-II peptide (Table 1) [25].
MT-II is a 23-membered ring formed from lactam cycli-
zation through the Lys and Asp side chains. The bioactive
conformation of MT-II involves a stable type 2 b-turn
around the core His-DPhe-Arg-Trp region, compared with
the type 3 b-turn of its linear analog, and the three
hydrophobic aromatic rings in a stacked orientation
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opposite the hydrophilic side chain of Arg [25]. As a
consequence, MT-II has a high affinity for melanocortin
receptors.
Investigations on the effects of modifications at the N-
terminal of MT-II and His-DPhe-Arg-Trp-NH2 peptides on
ligand potency [25] led us to believe that the affinity of
MT-II for the MC1 receptor would not be negatively
influenced by insertion of a bAla spacer and attachment of
a pz chelator to the N-terminus, yielding the cyclic con-
jugate pz-bAla-Nle-cyclo[Asp-DPhe-Arg-Trp-Lys]-NH2
(Scheme 1). To evaluate the advantages of lactam cycli-
zation in the pharmacokinetic profile and tumor-targeting
properties of the radioconjugates we also prepared and
assessed the biological properties of the respective linear
radioconjugate.
The cyclic and linear pz–peptide conjugates were pre-
pared by standard solid-phase synthetic methods, purified
by preparative RP-HPLC (purity 97% or better), and
characterized by ESI–MS (m/z = 1,303.87 and 1,321.6
[M + H]+ for the cyclic and the linear conjugate,
respectively).
The radioconjugates containing the linear peptide
([99mTc(CO)3-pz-bAla-Nle-Asp-DPhe-Arg-Trp-Lys-NH2])
and the cyclic peptide ([99mTc(CO)3-pz-bAla-Nle-
cyclo[Asp-DPhe-Arg-Trp-Lys]-NH2]) were prepared by
reaction of the precursor fac-[99mTc(CO)3(H2O)3]
+ (pre-
pared via an Isolink kit) with the conjugates at 90–
100 C, for 50–60 min (Scheme 1).
After optimization of the labeling conditions, namely,
temperature and reaction time, radiochemical yields higher
than 95% were obtained for both complexes using a final
concentration of conjugate of 6 9 10-5 M. The RP-HPLC
analytical retention times were 11.7 and 10.8 min for the
99mTc(CO)3-labeled cyclic and linear conjugates,
respectively.
In order to increase specific activity and to maximize
cellular and tumor uptake, the 99mTc(CO)3-labeled conju-
gates were separated from the corresponding nonmetallated
conjugates by semipreparative RP-HPLC. The fraction
corresponding to each radioconjugate was collected in a
50 mL Falcon vial containing PBS or MEM solutions with
0.2% BSA (for biodistribution or internalization studies,
respectively), to avoid adsorption phenomena, after evap-
oration of the HPLC elution solvent (CH3CN). The stability
of the radioconjugates in PBS and MEM solutions was
evaluated by HPLC and TLC, and it was found that no
interaction with BSA and/or transmetallation took place
under those conditions. Indeed, the HPLC chromatogram
(Supelguard LC 3 DP 2 cm 9 4.6 mm inner diameter col-
umn) of the cyclic radioconjugate, after 4 h incubation at
37 C in a 0.2% BSA solution in PBS, displays only the
radioconjugate (c-detection; retention time, 6.0 min) and
BSA (UV detection; retention time, 9.8 min). Furthermore,
on analyzing the TLC radiochromatogram of the cyclic
radioconjugate after 24 h incubation at 37 C in a 0.2%
BSA solution in MEM, we detected no hydrolyzed 99mTc
species (Rf = 0), labeled BSA (Rf = 0), [
99mTcO4]
-
(Rf = 0.85), or fac-[
99mTc(CO)3(H2O)3] precursor (Rf =
0.80), and the radiolabeled cyclic conjugate was the only
radiochemical species present (Rf = 0.44). A similar sta-
bility profile has been observed for the 99mTc(CO)3-labeled
linear conjugate. The results obtained with HPLC and TLC
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indicate that both the linear and the cyclic radiopeptide were
stable in the presence of BSA and MEM, and confirm the
high ability of the pyrazolyl-diamine chelator to stabilize
the fac-[99mTc(CO)3]
+ moiety, avoiding transmetallation
and/or reoxidation of the 99mTc(I) [31–34].
To assess the resistance of the radioconjugate to prote-
olytic degradation caused by endogenous peptidases and to
predict its in vivo stability, we performed stability assays in
fresh human plasma at 37 C. Analysis by RP-HPLC at
different incubation time points (0 min, 5 min, 45 min, and
4 h) indicated high plasma stability with negligible deg-
radation of both the linear and the cyclic radioconjugates,
and a purity of 98% or better. Again, it has been shown that
the pyrazolyl-diamine chelating unit is able to stabilize the
metal center against transmetallation reactions to serum-
based proteins.
The lipophilicity of both radiopeptides was evaluated by
determination of the partition coefficient in physiological
conditions. While the cyclic radioconjugate was moder-
ately hydrophobic (log Po/w = 0.196 ± 0.003), the linear
analog revealed a hydrophilic character (log Po/w =
-1.074 ± 0.010).
The degree of internalization in B16F1 murine mela-
noma cells is a very important parameter for predicting
tumor-targeting properties of the labeled peptides. Inter-
nalization studies performed for both radioconjugates, at
room temperature and at 37 C, revealed that the cellular
uptake was temperature-dependent and time-dependent
(Fig. 1).
As shown in Fig. 1, higher levels of internalization were
reached for the 99mTc(CO)3-labeled cyclic conjugate,
compared with the linear one. For instance, at 4 h after
incubation (37 C), while only approximately 30% of the
total cell-associated activity for the administered linear
radioconjugate was taken up and internalized by the cells,
79% was internalized for the cyclic radiopeptide (Fig. 1,
panels A, B). A striking difference between the levels of
internalization is observed when this parameter is expres-
sed as a percentage of total activity (Fig. 1, panel C). In
fact, while a negligible amount of radioactivity (1.6%) was
internalized after 4 h for the linear radiopeptide, a
remarkable internalization (41.8 and 50.5% for 4 and 6 h,
respectively) was attained for the cyclic radioconjugate.
These values are particularly high when compared with
data previously reported for other radiolabeled a-MSH
analogs. Indeed, for 64Cu-DOTA-NAPamide and
99mTc(CO)3-pz-NAPamide the maximum internalization
observed was approximately 4.5% of the applied activity
3 h after incubation [9, 20]. In the case of the cyclic ra-
diopeptide 99mTc-CCMSH, using the same experimental
conditions as those used for the 99mTc(CO)3-labeled cyclic
conjugate (0.2 9 106 melanoma B16F1 cells per well and
200,000 cpm of radioconjugate per well), the maximum
internalization achieved was less than 4% [17].
The cellular retention of the radioconjugates was also
evaluated in B16F1 cells at different time points (Fig. 2). A
moderate retention was observed for the linear radiocon-
jugate, with 35.3% of the cell-associated activity still
remaining inside the cells after 4 h. In the case of the cyclic
radioconjugate, a remarkably higher degree of cellular
retention was observed. Indeed, the 99mTc(CO)3-labeled
cyclic conjugate was slowly released from the cells into the
medium, with about 75% of the radioactivity still associ-
ated with the cells even after 5 h incubation. The enhanced
internalization and intracellular retention of the cyclic
radioconjugate, compared with that of its linear counter-
part, is much likely related with the compact structure of
the former. In fact, this structure seems to confer a more
potent agonistic binding behavior to the peptide and an
increased resistance to proteolysis.
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The biodistribution of 99mTc(CO)3-labeled a-MSH
analogs was examined in a B16F1 melanoma-bearing
mouse model, at 1, 4, and 24 h after intravenous injection.
Biodistribution data for the linear and the cyclic radio-
conjugate are presented in Tables 2 and 3, respectively.
Biodistribution data from the linear radioconjugate
indicate a fast clearance from the bloodstream
[0.40 ± 0.05% injected dose (ID)/g, 4 h after injection]
and other main organs, including skeletal and soft tissues
like muscle. The overall radioactivity elimination occurs
mainly by the urinary excretion route as indicated by the
percentage of total excretion (56.4% at 1 h after injection),
which predominantly corresponds to urine. Nevertheless, a
significant portion of radioactivity is rapidly taken up by
the liver and cleared into intestines, suggesting the
importance of the hepatobiliary excretion pathway
(11.7 ± 2.6 and 18.4 ± 3.1% ID per organ at 1 h after
injection; 2.1 ± 0.8 and 26.8 ± 2.4% ID per organ at 4 h
after injection, for liver and intestine, respectively).
The effect of cyclization on the biodistribution profile of
the radioconjugate was mainly reflected in the decrease of
clearance from most organs and in the radioactivity
retained in the excretory organs, like liver and kidney. As a
consequence of this behavior, the overall excretion from
the whole animal body was significantly low. Indeed, 1 h
after injection only 14.2% of the total activity was elimi-
nated and 67% of that activity still remained in the animal
4 h after injection.
Owing to the high liver mass, the uptake for the cyclic
analog in this organ was relatively high (23.5 ± 1.3% ID
per organ, 4 h after injection), when compared with the
kidney uptake (9.2 ± 0.7% ID per organ, 4 h after injec-
tion). Nevertheless, this result could be predicted from the
lipophilic character (log Po/w = 0.196 ± 0.003) presented
by the cyclic radioconjugate. A shift from the hepatobiliary
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Fig. 2 Cellular retention of internalized linear and cyclic radiocon-
jugates in B16F1 cells over time at 37 C
Table 2 Biodistribution of the 99mTc(CO)3-labeled linear conjugate in B16F1 murine melanoma-bearing C57BL/6 mice at 1, 4, and 24 h after
intravenous injection (mean ± standard deviation, n = 4–5)
Tissue/organ Percentage ID/g ± standard deviation
1 h 4 h 4 h with NDPa 24 h
Tumor 1.96 ± 0.17 0.99 ± 0.08 0.55 ± 0.11 0.027 ± 0.010
Blood 1.08 ± 0.28 0.40 ± 0.05 0.37 ± 0.06 0.011 ± 0.002
Liver 11.28 ± 1.28 2.02 ± 0.82 1.36 ± 0.39 0.033 ± 0.002
Intestine 10.37 ± 2.36 16.18 ± 3.75 19.70 ± 2.29 0.056 ± 0.048
Spleen 1.42 ± 0.11 0.30 ± 0.05 0.31 ± 0.08 0.018 ± 0.004
Heart 0.35 ± 0.01 0.11 ± 0.02 0.10 ± 0.02 0.004 ± 0.001
Lung 1.14 ± 0.13 0.34 ± 0.09 0.44 ± 0.10 0.012 ± 0.002
Kidney 7.77 ± 0.57 1.64 ± 0.19 1.59 ± 0.21 0.029 ± 0.001
Muscle 0.25 ± 0.12 0.10 ± 0.06 0.03 ± 0.01 0.002 ± 0.001
Bone 0.36 ± 0.05 0.08 ± 0.02 0.07 ± 0.01 0.003 ± 0.001
Stomach 2.17 ± 1.45 0.73 ± 0.50 0.47 ± 0.26 0.031 ± 0.022
Adrenals 1.10 ± 0.07 0.32 ± 0.20 0.38 ± 0.11 0.012 ± 0.001
Pancreas 0.25 ± 0.05 0.16 ± 0.08 0.44 ± 0.19 0.002 ± 0.000
Skin 0.38 ± 0.03 0.08 ± 0.03 0.08 ± 0.03 0.002 ± 0.001
Uptake ratio of tumor to normal tissue
Tumor/blood 1.8 2.5 1.5 2.4
Tumor/muscle 7.8 9.9 18.3 13.5
Total excretion (%) 56.4 ± 5.8 64.4 ± 4.3 63.6 ± 3.4 96.0 ± 2.6
ID injected dose, NDP (Nle4,DPhe7)-aMSH
a Coinjection of the radioconjugate with NDP
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towards the renal excretion pathway could be achieved by
reducing the lipophilicity of the radiopeptide by introduc-
ing Asp or Glu residues (polar, negatively charged, and
very hydrophilic amino acids) in the peptide sequence. No
significant uptake or retention of radioactivity in the
stomach was observed for both radioconjugates, indicating
minimal, if any, in vivo oxidation of the complexes to
[99mTcO4]
-.
The most striking difference between the two
99mTc(CO)3-labeled conjugates is related to tumor uptake.
While a low tumor uptake for the 99mTc-labeled linear
peptide was found (1.96 ± 0.17 and 0.99 ± 0.08% ID/g at
1 and 4 h after injection, respectively), a fast and remark-
able activity accumulation in the MC1R-expressing B16F1
tumor was observed for the cyclic radioconjugate. Indeed,
1 h after injection, a tumor uptake of 9.26 ± 0.83% ID/g
was found, with this value increasing slowly to
11.31 ± 1.83% ID/g at 4 h after injection. The activity was
then slowly washed out from the tumor, and the uptake
dropped to a still relevant value of 3.48 ± 0.40% ID/g over
24 h. The high tumor uptake and the high tumor retention
are in agreement with the high internalization and slow
washout observed in in vitro studies with B16F1 cells for
the cyclic radioconjugate, reflecting again the advantages
of lactam cyclization in MC1R affinity and potency and in
resistance to intracellular degradation.
The in vivo specificity of the radioconjugates for the
MC1R was evaluated by their coadministration with cold
NDP-MSH peptide (linear a-MSH peptide analog with
picomolar affinity for the MC1R expressed on murine
melanoma cells) in the same animal model. The receptor-
blocking studies at 4 h after injection revealed that the
tumor uptake was significantly reduced by 74.8 and 44.5%
for the cyclic and linear radioconjugates, respectively, in
the presence of NDP-MSH, without significant changes in
the biodistribution profile of the radioconjugates in healthy
tissues (Tables 2, 3). These results confirmed that tumor
uptake of both radioconjugates is MC1R-mediated, and
that both peptides kept their biological activity upon con-
jugation to the pz-containing chelator and consequent
99mTc(CO)3 labeling. Tumor-to-blood and tumor-to-muscle
uptake ratios were higher for the cyclic than for the linear
radioconjugate despite the slow clearance from nontarget
organs. Furthermore, for the cyclic radioconjugate the
tumor-to-blood and tumor-to-muscle uptake ratios
increased from 6.8 and 61.4 (4 h after injection) to 17.4
and 116 (24 h after injection), which also indicates a
receptor-mediated transport, and subsequent intracellular
trapping of this radiocomplex in the MC1R-expressing
tumor.
The high tumor uptake and retention found for the
99mTc(CO)3-labeled cyclic conjugate, compared with its
linear counterpart, is in full agreement with the data
obtained for the cyclic 99mTc/Re-CCMSH analog, using the
same animal model (B16F1 melanoma-bearing C57BL/6
mice) [10, 17]. The linear, nonmetallated, 111In-DOTA-
Table 3 Biodistribution of the 99mTc(CO)3-labeled cyclic conjugate in B16F1 murine melanoma-bearing C57BL/6 mice at 1, 4, and 24 h after
intravenous injection (mean ± standard deviation, n = 4–5)
Tissue/organ Percentage ID/g ± standard deviation
1 h 4 h 4 h with NDPa 24 h
Tumor 9.26 ± 0.83 11.31 ± 1.83 2.97 ± 0.62 3.48 ± 0.40
Blood 2.71 ± 0.64 1.67 ± 0.24 1.46 ± 0.13 0.20 ± 0.05
Liver 42.19 ± 5.05 22.86 ± 1.17 24.69 ± 3.16 1.72 ± 0.12
Intestine 5.17 ± 0.91 8.45 ± 0.76 11.00 ± 1.04 1.15 ± 0.37
Spleen 2.54 ± 0.28 2.24 ± 0.37 1.86 ± 0.37 0.46 ± 0.09
Heart 1.04 ± 0.19 0.48 ± 0.07 0.44 ± 0.05 0.15 ± 0.01
Lung 3.85 ± 0.46 1.54 ± 0.16 1.72 ± 0.32 0.90 ± 0.52
Kidney 71.06 ± 6.44 32.12 ± 1.57 42.37 ± 3.07 1.48 ± 0.24
Muscle 0.35 ± 0.07 0.19 ± 0.08 0.18 ± 0.06 0.03 ± 0.00
Bone 1.14 ± 0.19 0.70 ± 0.13 0.48 ± 0.04 0.09 ± 0.01
Stomach 1.97 ± 0.75 0.88 ± 0.46 0.93 ± 0.27 0.25 ± 0.30
Pancreas 0.73 ± 0.32 0.39 ± 0.10 0.26 ± 0.04 0.07 ± 0.01
Skin 0.84 ± 0.12 0.53 ± 0.10 0.57 ± 0.10 0.13 ± 0.08
Uptake ratio of tumor to normal tissue
Tumor/blood 3.4 6.8 2.0 17.4
Tumor/muscle 26.5 61.4 16.5 116
Total excretion (%) 14.2 ± 2.3 37.4 ± 2.4 33.0 ± 1.5 87.6 ± 3.2
a Coinjection of the radioconjugate with NDP
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CCMSH exhibited also a lower tumor uptake than the
homolog 111In-DOTA-ReCCMSH (4.32 ± 0.59 vs.
9.49 ± 0.90% ID/g, 4 h after injection), clearly showing
the benefit of ReO-mediated cyclization or peptide cycli-
zation itself [10]. The best tumor uptake obtained with
111In-DOTA-ReCCMSH (ReO cyclization) compared with
the disulfide-bond-cyclized analog 111In-DOTA-CMSH
indicated that different methods of peptide cyclization
yield molecules with different in vivo biodistribution
properties [10]. In addition, 111In-DOTA-ReCCMSH
exhibited again superior tumor retention values compared
with the cyclic 99mTc-CCMSH at 24 h after injection
(4.86 ± 1.52 vs. 1.38 ± 0.36% ID/g), although they were
not statistically different at early time points [10, 17].
Herein, we have demonstrated that the cyclization through
a lactam bridge appears to be another promising method of
peptide cyclization for radiolabeled a-MSH analogs.
The 99mTc(CO)3-labeled linear conjugate presents a
very low tumor uptake (1.96 ± 0.17 and 0.99 ± 0.08% ID/
g at 1 and 4 h after injection, respectively). The same
peptidic linear sequence, previously labeled with 111In
using the DOTA chelator, displayed also a relatively low
tumor uptake without significant retention (4.31 ± 0.30
and 1.17 ± 0.13% ID/g for 4 and 24 h, respectively) [19].
These results taken together indicate that a constrained
structure, conferred by lactam-based cyclization in this
particular amino acid sequence, significantly favors the
peptide–MC1R interaction.
However, cyclization of the linear peptide through lac-
tam formation led to an impressive increase in kidney
uptake (for the linear peptide 1.64 ± 0.19% ID/g and for
the cyclic peptide 32.12 ± 0.19% ID/g, at 4 h after injec-
tion). Since it is well established that administration of
cationic amino acids (Lys and Arg) inhibits renal accu-
mulation of radiolabeled proteins and peptides [42, 43], we
performed a second set of biodistribution experiments in
healthy mice in which Lys was coinjected with the cyclic
radioconjugate (Table 4). Interestingly, coadministration of
this basic amino acid did not reduce significantly kidney
accumulation of 99mTc(CO)3-labeled cyclic peptide, which
seems to indicate that the electrostatic interaction between
the positively charged complex and the negatively charged
surface of the proximal tubule cells is not a major factor for
tubular reabsorption. This behavior has already been
observed for similar a-MSH analogs labeled with other
radiometals [M-DOTA-Re(Arg11)CCMSH; M is 90Y,
177Lu] [44]. In these studies, the multiligand megalin
receptor, strongly expressed in the renal proximal tubule,
was proposed as the main system involved in the renal
uptake of the complexes [45, 46].
In vivo stability studies revealed that both linear and
cyclic radioconjugates are stable in blood (1 h after
injection), as no metabolites could be detected (Fig. 3).
The plasmatic protein-bound fraction for the radioconju-
gates was relatively low (21 and 22% for cyclic and linear
radioconjugates, respectively). These results indicate again
that metal complexation via the tridentate pyrazolyl-
diamine backbone overcomes potential binding/transmet-
allation to coordinating residues in circulating proteins,
Table 4 Biodistribution of the 99mTc(CO)3-labeled cyclic conjugate
coinjected with or without 15 mg of L-Lys in healthy C57BL/6 mice, at
1 h after intravenous injection (mean ± standard deviation, n = 4–5)
Tissue/organ Percentage ID/g ± standard deviation
With L-Lys Without L-Lys
Blood 3.03 ± 1.75 2.83 ± 1.04
Liver 28.15 ± 4.05 24.71 ± 1.94
Intestine 2.79 ± 0.72 2.70 ± 0.68
Spleen 1.87 ± 0.36 2.39 ± 0.66
Heart 0.96 ± 0.30 0.86 ± 0.14
Lung 2.67 ± 0.95 2.07 ± 1.03
Kidney 49.44 ± 5.87 59.38 ± 11.79
Muscle 0.30 ± 0.08 0.31 ± 0.05
Bone 0.75 ± 0.30 0.79 ± 0.21
Stomach 3.36 ± 1.57 4.62 ± 2.94
Adrenals 11.31 ± 8.61 4.98 ± 2.29
Pancreas 0.44 ± 0.15 0.66 ± 0.48
Skin 1.08 ± 0.15 1.15 ± 0.18
Total excretion (%) 17.0 ± 2.2 12.7 ± 2.2
urine
blood
injected
preparation
Linear radiopeptide
5
Cyclic radiopeptide
11.8 min
11.6 min
11.8 min
10.1 min
10.8 min
10.9 min
10.9 min
10.4 min
12.0 min
1715131197 5 1715131197
Fig. 3 Reversed-phase high-performance liquid chromatography
chromatograms of the injected preparation, blood serum, and urine
samples collected 1 h after injection
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such as His, Cys, or Met. In contrast, metabolites from both
radioconjugates were found in urine. While a more hydro-
phobic species was observed for the linear radioconjugate
(retention time 12.0 vs. 10.9 min), the metabolites of the
cyclic radioconjugate were essentially hydrophilic species
with the major metabolite appearing at 10.1 min.
In conclusion, we have prepared a MT-II-based cyclic
99mTc(CO3) radiopeptide and the corresponding linear
analog in high yield and radiochemical purity. Both
radioconjugates displayed good stability in vitro and in
vivo. The cyclization through a lactam bridge resulted in a
compact structure that remarkably enhanced the cellular
internalization and retention, and consequently MC1R-
mediated tumor uptake in B16F1 melanoma-bearing mice.
Despite the promising tumor-targeting properties exhibited
by the cyclic radiopeptide, its pharmacokinetic profile has
still to be improved. Higher excretion and lower kidney
uptake can certainly be reached either by modifying the
physicochemical properties of the bifunctional chelating
agent (e.g., charge and hydrophilicity) or by changing some
of the amino acids of the peptide.
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